<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902041</url>
  </required_header>
  <id_info>
    <org_study_id>SDPH001</org_study_id>
    <nct_id>NCT03902041</nct_id>
  </id_info>
  <brief_title>The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT</brief_title>
  <official_title>The Prospective Randomized Controlled Clinical Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of Eltrombopag after Hematopoietic stem cell
      transplantation (HSCT) to improve the engraftment of hematopoietic stem cell. Half of the
      participants will receive Eltrombopag,while the other will not receive the Eltrombopag.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the progress of transplantation technology，allogeneic hematopoietic stem cell
      transplantation is becoming an important treatment for hematological diseases and the
      long-term survival of patients is gradually improved. However, thrombocytopenia after
      transplantation has always been an important complication. Studies have shown that about 20%
      patients had different degrees of thrombocytopenia. Eltrombopag could promote hematopoietic
      stem cell proliferation and differentiation in vitro studies. It has also been widely used in
      the treatment of immune thrombocytopenia (ITP) and aplastic anemia(AA) and increased platelet
      levels in such diseases. Eltrombopag is also used to treat poor platelet engraftment after
      transplantation and the effective rate is about 60%-80%. Therefore, the application of
      Eltrombopag at early time after transplantation might promote platelet engraftment and reduce
      platelet transfusions.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The engraftment of platelet</measure>
    <time_frame>3 years</time_frame>
    <description>the day of platelet engraftment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The levels of platelet</measure>
    <time_frame>3 years</time_frame>
    <description>The levels of platelet at 30 days after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of platelet transfusions</measure>
    <time_frame>3 years</time_frame>
    <description>The number of platelet units be transfused to the patients before platelet engraftment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The engraftment of white blood cell</measure>
    <time_frame>3 years</time_frame>
    <description>The day of white blood cell engraftment</description>
  </other_outcome>
  <other_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>3years overall survival of the patients</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation</condition>
  <condition>Eltrombopag</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <description>The patients will receive Eltrombopag treatment after transplantation at d1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>The patients will not receive Eltrombopag treatment after transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>The patients will receive Eltrombopag treatment after transplantation</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients after allogeneic hematopoietic stem cell transplantation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with definite diagnosis of hematological diseases, more than 30 kg, age18-60
             years, gender and race are not limited;

          2. Acceptance of allogeneic hematopoietic stem cell transplantation;

          3. Voluntary acceptance of the study

        Exclusion Criteria:

          1. Patients with severe organ dysfunction or disease；

          2. Patients who cannot tolerate oral Eltrombopag therapy;

          3. Patients who refuse all-HSCT and Eltrombopag treatment;

          4. Patients that investigator believed not suitable for enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaosheng Fang</last_name>
    <phone>15168889703</phone>
    <email>fxsh_1010@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Wang</last_name>
    <email>xinw007@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heamtology Department, Provincial Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaosheng Fang</last_name>
      <phone>15168889703</phone>
      <email>fxsh_1010@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin Wang</last_name>
      <email>xinw007@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Wang Xin</investigator_full_name>
    <investigator_title>Director of Hematology Department</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

